| Name | Title | Contact Details |
|---|
Magellan Diagnostics is a North Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AeroCare Holdings is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ChartSpan is a healthcare data company serving patients, providers and employers. Consumers use ChartSpan`s Patient Platform to manage their electronic healthcare records and information on their smartphone, tablet or computer. ChartSpan`s iPhone, iPad, Android and Android Tablet apps have all become the #1 most downloaded medical apps in the U.S. Providers (hospitals, clinics and doctors) leverage ChartSpan`s consumer products to deliver world-class patient EaaS (Engagement-as-a-Service™) to their patients. Employers utilize ChartSpan`s consumer products to manage wellness and healthcare analytics within its employee population.
Parrish Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Parrish Medical Center is based in Titusville, FL. You can find more information on Parrish Medical Center at www.parrishmed.com
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.